Rossdorf, Germany

J Urgen Eckstein

This inventor holds 1 USPTO granted patent. Top assignee: Merck Patent Gesellschaft MIT Beschrankter Haftung. Active years: 1997.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: J Urgen Eckstein: Innovator in Ketotricyclo Derivatives

Introduction

J Urgen Eckstein is a notable inventor based in Rossdorf, Germany. He has made significant contributions to the field of chemistry, particularly in the development of ketotricyclo derivatives. His work has implications in various applications, showcasing the importance of innovation in scientific research.

Latest Patents

Eckstein holds a patent for ketotricyclo[5.2.1.0]decane derivatives. This invention relates to compounds of the formula I, wherein Phe is a phenyl group that can be unsubstituted or substituted by 1 to 5 hydroxyl, alkyl, or alkoxy groups containing 1 to 10 carbon atoms. This patent highlights his expertise in creating complex chemical structures with potential applications in pharmaceuticals and materials science.

Career Highlights

Eckstein is associated with Merck Patent Gesellschaft mit beschränkter Haftung, a leading company in the pharmaceutical and chemical industry. His role at Merck has allowed him to engage in cutting-edge research and development, contributing to the company's innovative portfolio.

Collaborations

Throughout his career, Eckstein has collaborated with esteemed colleagues such as Michael Schwarz and Ingeborg Stein. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

J Urgen Eckstein's contributions to the field of chemistry, particularly through his patent on ketotricyclo derivatives, exemplify the vital role of inventors in advancing scientific knowledge. His work continues to inspire innovation within the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…